SaluTech

SaluTech is developing a safe Conductive Biomaterial (CBM) to treat cardiac arrhythmia by resynchronizing the electrical propagation in the heart. CBM is a non-toxic, long-lasting, and biocompatible nano-membrane that is able to mimic the conductive velocity of healthy heart tissue. The technology was originally developed within the University Health Network, and is patent protected. SaluTech is currently completing large animal studies, and looking to move forward to start clinical trials.

Ren-Ke Li,

Co-Founder and Chief Scientific Officer
renkeli@uhnresearch.ca

Shuhe Li,

Co-Founder and Chief Executive Officer
shuhe.li@salutechlimited.com